1,520 Shares in Humana Inc. (NYSE:HUM) Bought by RPS Advisory Solutions LLC

RPS Advisory Solutions LLC acquired a new stake in Humana Inc. (NYSE:HUM) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 1,520 shares of the insurance provider’s stock, valued at approximately $386,000.

A number of other large investors have also modified their holdings of the company. Pinnacle Wealth Management Advisory Group LLC grew its position in shares of Humana by 3.6% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after purchasing an additional 37 shares during the period. Atlas Brown Inc. boosted its holdings in Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock worth $1,611,000 after buying an additional 38 shares during the last quarter. Moors & Cabot Inc. increased its stake in Humana by 2.5% during the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after buying an additional 40 shares in the last quarter. Mather Group LLC. raised its holdings in shares of Humana by 21.0% during the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after acquiring an additional 41 shares during the last quarter. Finally, Your Advocates Ltd. LLP lifted its position in shares of Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.32% of the stock is owned by corporate insiders.

Humana Stock Performance

Shares of Humana stock opened at $271.87 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $32.74 billion, a price-to-earnings ratio of 27.32, a price-to-earnings-growth ratio of 1.94 and a beta of 0.56. The business has a 50-day moving average of $269.78 and a 200 day moving average of $291.15. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, sell-side analysts forecast that Humana Inc. will post 16.49 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.30%. Humana’s dividend payout ratio (DPR) is 35.58%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on HUM shares. Truist Financial increased their price objective on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. TD Cowen raised their price target on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Morgan Stanley dropped their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Piper Sandler boosted their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Finally, Barclays upped their price target on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.